002826 Stock Overview
Engages in the research and development, manufacturing, and sale of medical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 002826 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Tibet AIM Pharm. Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥12.24 |
| 52 Week High | CN¥13.62 |
| 52 Week Low | CN¥5.57 |
| Beta | 0.29 |
| 1 Month Change | 8.70% |
| 3 Month Change | 59.79% |
| 1 Year Change | 4.79% |
| 3 Year Change | 16.02% |
| 5 Year Change | 24.39% |
| Change since IPO | 40.21% |
Recent News & Updates
What Tibet AIM Pharm. Inc.'s (SZSE:002826) 28% Share Price Gain Is Not Telling You
Nov 26
Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality
Nov 06Recent updates
What Tibet AIM Pharm. Inc.'s (SZSE:002826) 28% Share Price Gain Is Not Telling You
Nov 26Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality
Nov 06Some Confidence Is Lacking In Tibet AIM Pharm. Inc.'s (SZSE:002826) P/E
Jun 07Investors Can Find Comfort In Tibet AIM Pharm's (SZSE:002826) Earnings Quality
May 02Risks Still Elevated At These Prices As Tibet AIM Pharm. Inc. (SZSE:002826) Shares Dive 26%
Feb 29Shareholder Returns
| 002826 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -3.7% | -1.9% | -1.2% |
| 1Y | 4.8% | -1.8% | 11.8% |
Return vs Industry: 002826 exceeded the CN Pharmaceuticals industry which returned -1.8% over the past year.
Return vs Market: 002826 underperformed the CN Market which returned 11.8% over the past year.
Price Volatility
| 002826 volatility | |
|---|---|
| 002826 Average Weekly Movement | 8.5% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 002826 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002826's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 439 | Zhou Min | www.emyy.cn |
Tibet AIM Pharm. Inc. engages in the research and development, manufacturing, and sale of medical products in China. The company’s products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; and NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain, as well as coma, spinal cord injury, cerebral infarction, hemorrhage, etc. It also provides Carbetocin injections for prevention of postpartum hemorrhage; Domperidone tablets for treatment of indigestion, abdominal bloating, belching, nausea, vomiting, and abdominal distension and pain; Montmorillonite powder for chronic diarrhea; Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotics, antiallergic, and digestive systems.
Tibet AIM Pharm. Inc. Fundamentals Summary
| 002826 fundamental statistics | |
|---|---|
| Market cap | CN¥2.25b |
| Earnings (TTM) | CN¥33.32m |
| Revenue (TTM) | CN¥641.58m |
67.4x
P/E Ratio3.5x
P/S RatioIs 002826 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002826 income statement (TTM) | |
|---|---|
| Revenue | CN¥641.58m |
| Cost of Revenue | CN¥219.10m |
| Gross Profit | CN¥422.48m |
| Other Expenses | CN¥389.17m |
| Earnings | CN¥33.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.18 |
| Gross Margin | 65.85% |
| Net Profit Margin | 5.19% |
| Debt/Equity Ratio | 1.1% |
How did 002826 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield18%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 12:40 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tibet AIM Pharm. Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|